TGEN - Targeted Genetics Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation

TGEN 8.230

+0.9%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (362)	5/21/2002 11:16:31 PM
From: Mike McFarland	of 557

Today Targeted Genetics presented interim results of its ongoing Phase I clinical trial in patients with advanced ovarian cancer at the 38th Annual Meeting of the American Society of Clinical Oncology in Orlando, Florida targetedgenetics.com "Previous clinical and preclinical studies have shown the potential utility of tgDCC-E1A in slowing tumor growth and sensitizing tumors to chemotherapeutic agents. Additionally, many ovarian cancers are extremely aggressive and can be associated with resistance to chemotherapy, metastasis and poor prognosis. Data supporting the ability of E1A to down-regulate expression of certain oncogenes further strengthens the rationale for developing tgDCC-E1A as a treatment for ovarian cancer," said Barrie J. Carter, Executive Vice President and Chief Scientific Officer at Targeted Genetics Corporation. "We are pleased that the study results have shown tgDCC-E1A to be well-tolerated, with a good safety profile. We look forward to presenting results of the completed study at the end of the year."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next